

Rheumatology Enrollment Form A-K

350	02 U.S. Highway 9. Howell. N	J. 07731 www. parkw	aysp.com Email: PATIENT INF		vaysp.com Phone: 1-866-355	-//9/ Fax: 1-888-551-6289		
Name:			Date of Birth:		O Male O Female	O Male O Female		
Address:			City:	State:	ate: Zip:			
Phone:			Alt Phone:		Fmail [.]	Email:		
SS#:			Primary Language:			Emergency Contact:		
			PRESCRIBER IN	NEODMATION	Line geney contact.			
Proceribing Practi	tioner		F RESCRIBER II	VI ORMATION	NPI#:			
Prescribing Practitioner: Supervising Physician:					NPI#. NPI#:			
Address: City:			State:	Zip:	Tax ID:	Tax ID:		
Phone: Fax:						Office Contact:		
			PRESCRIPTION	INFORMATIO	<u></u>			
Needs by Date:		Ship to: O Patients I			O Prescriber all orders O Othe	r		
Drug	Dose	Direction & Quantities				Refills		
O A -t®	O Vials	O IV: Infuse mg OR mg/kg via IV every 4 weeks (Quantity:)						
O Actemra®	O Pre-filled Syringe	O SQ: Inject 162 mg SQ every other week (Quantity: 2) O SQ: Inject 162 mg SQ every week (Quantity: 4)						
: 	O Pre-filled Syringe	O INITIAL: Inject 400 mg SQ at Day 0, Day 14, and Day 28 (Quantity: 6)						
O Cimzia®	O Vials	O MAINTENANCE: Inje	ct 400 mg SQ every	4 weeks (Qua	ntity: 2)			
		O MAINTENANCE: Inject 200 mg SQ every 2 weeks (Quantity: 2)						
O Cosentyx [®]	O Sensoready Pen	O INITIAL: Inject 150 mg SQ on week 0, 1, 2, 3, and 4 (Quantity: 5) O MAINTENANCE: Inject 150 mg SQ every 4 weeks (Quantity: 1)						
	O Pre-filled Syringe	[
		O MAINTENANCE: Inject 300 mg SQ every 4 weeks (Quantity: 2)						
O Enbrel®	O SureClick® Pen	O Inject 50 mg SQ every week (Quantity: 4)						
	O Mini™ with AutoTouch™							
	O Pre-filled Syringe O 25 mg O 50 mg	O Inject mg (0.8 mg/kg x kg) SQ every week						
	O Vials 25mg	O injecting	(0.0 mg/kg x	kg/ 3Q ever	y week			
0 H	O Pen	O UVEITIS INITIAL: Inject 80mg SQ on Day 1, 40mg on Day 8, then 40mg every other week (1 Kit)						
O Humira® O Pre-filled Syringe O MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)								
O MAINTENANCE: Inject 40 mg SQ weekly (Quantity: 4) O Pre-filled Syringe O Inject 150 mg SQ every 2 weeks (Qty: 2)								
O Kevzara®	O 150 mg O 200 mg	O Inject 150 mg SQ ev)				
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	MEDICAL INF			·		
PREVIOUS THERA					AS WELL AS ANY CLINICAL NOTE			
}	AME2:	Tried & Failed (Dur	ation): Not	Tolerated:		ontraindication:		
O Methotrexate		0 ()	0				
O Plaquenil		0 ()	0				
O Sulfasalazine		0 ()	0				
O Meloxicam		0 ()	0				
O Naproxen / Aleve		0 ()	0				
O Tramadol		0 ()	0				
O Enbrel		0 ()	0				
O Humira		0 ()	0				
O Cimzia O ()	0				
00()	0				
O H20.9 Unspeci	•		•		pecified Acute and Subacute			
O M31.6 Other Gi	toid Arthritis, Unspecified ant Cell Arteritis				n Rheumatoid Factor, Unspecified ithout Rheumatoid Factor, Unspeci	fied		
1	ing Spondylitis, Unspecified				neumatoid Arthritis of Unspecified			
O M31.5 Giant Ce	ll Arteritis with Polymyalgia Rheu	matica	O Other:					
Date of Diagnosis	S:	Allergies:						
Active TB is ruled	out: O Yes O No Date:		B ruled out/treated:	O Yes O No	Date:/			
Patient Height:	in/cm V	/eight:	kg/lbs					
Additional Clinica	I Information:		_IN IECTION	TRAINING				
O Patient has rec	eived pen and injection training	O Physician's of	INJECTION fice to provide inject		O Parkway Pharmacy to coord	inate injection training		
		Pi	RESCRIBING PRACT	TITIONER SIGN	ATURE			
				ng Parkway Ph	armacy to serve as your prior autho	rization designated agent in dealing with		
medical and pres	cription insurance companies, and	u co-pay assistance toun	ианопѕ.					
Prescribing Prac	titioner:				Date			
			CONFIDENTIA	ALITY NOTICE				

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.